Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Martin Cullell-Young"'
Autor:
Vincent Ribrag, Dolores Caballero, Christophe Fermé, Emanuele Zucca, Reyes Arranz, Javier Briones, Christian Gisselbrecht, Gilles Salles, Alessandro M. Gianni, Henry Gomez, Carmen Kahatt, Claudia Corrado, Sergio Szyldergemajn, Sonia Extremera, Bernardo de Miguel, Martin Cullell-Young, Franco Cavalli
Publikováno v:
Haematologica, Vol 98, Iss 3 (2013)
This phase II clinical trial evaluated the efficacy, safety and pharmacokinetics of plitidepsin 3.2 mg/m2 administered as a 1-hour intravenous infusion weekly on days 1, 8 and 15 every 4 weeks in 67 adult patients with relapsed/refractory aggressive
Externí odkaz:
https://doaj.org/article/c58afd14cd994b96ba309fccf26fa18d
Autor:
Vivek Subbiah, Irene Braña, Alessandra Longhi, Valentina Boni, Jean-Pierre Delord, Ahmad Awada, Pascaline Boudou-Rouquette, John Sarantopoulos, Geoffrey I. Shapiro, Anthony Elias, Ravin Ratan, Cristian Fernandez, Carmen Kahatt, Martin Cullell-Young, Mariano Siguero, Ali Zeaiter, Sant P. Chawla
Publikováno v:
Scientia
Purpose: Lurbinectedin suppresses the oncogenic transcription factor EWS-FLI1 through relocalization to the nucleolus, and delays tumor growth in mice bearing Ewing sarcoma xenografts. On the basis of this rationale, lurbinectedin was evaluated in pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8100524bd4d5c095d14707970e0985c
https://doi.org/10.1158/1078-0432.ccr-22-0696
https://doi.org/10.1158/1078-0432.ccr-22-0696
Autor:
Emiliano Calvo, Cristiana Sessa, Guilherme Harada, Maria de Miguel, Carmen Kahatt, Xarles Erik Luepke-Estefan, Mariano Siguero, Carlos Fernandez-Teruel, Martin Cullell-Young, Anastasios Stathis, Alexander Drilon
Publikováno v:
Investigational new drugs. 40(6)
SummaryLurbinectedin and paclitaxel showed synergism in preclinical studies and have non-completely overlapping toxicity profiles. This phase I trial evaluated a combination of paclitaxel and lurbinectedin with/without bevacizumab in advanced tumors.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::062446b9247e21143ff246c46ddaf5e9
https://pubmed.ncbi.nlm.nih.gov/35947247
https://pubmed.ncbi.nlm.nih.gov/35947247
Autor:
Santiago Ponce Aix, Tudor Eliade Ciuleanu, Alejandro Navarro, Sophie Cousin, Laura Bonanno, Egbert F Smit, Alberto Chiappori, Maria Eugenia Olmedo, Ildiko Horvath, Christian Grohé, Anna F Farago, José Antonio López-Vilariño, Martin Cullell-Young, Antonio Nieto, Noelia Vasco, Javier Gómez, Carmen Kahatt, Ali Zeaiter, Enric Carcereny, Jaromir Roubec, Konstantinos Syrigos, Gregory Lo, Isidoro Barneto, Anthony Pope, Amparo Sánchez, Joseph Kattan, Konstantinos Zarogoulidis, Cornelius F Waller, Helge Bischoff, Oscar Juan-Vidal, Niels Reinmuth, Manuel Dómine, Luis Paz-Ares
Publikováno v:
The Lancet. Respiratory medicine. 11(1)
Lurbinectedin is a synthetic marine-derived anticancer agent that acts as a selective inhibitor of oncogenic transcription. Lurbinectedin monotherapy (3·2 mg/mIn this phase 3, open-label, randomised study, adult patients aged 18 years or older with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce6f52ade7216d6da6b59b8fe822e10f
https://pubmed.ncbi.nlm.nih.gov/36252599
https://pubmed.ncbi.nlm.nih.gov/36252599
Autor:
J.A. Lopez-Vilariño, Victor Moreno, Rafael Nuñez, Michael Flynn, Carmen Kahatt, Martin Forster, Irene Brana, Maria Eugenia Olmedo, Bernard Doger, Ali Zeaiter, Maria de Miguel, Emiliano Calvo, Martin Cullell-Young, María Pilar López-Criado
Publikováno v:
Investigational New Drugs
Scientia
Scientia
SummaryBackground A phase I study found remarkable activity and manageable toxicity for doxorubicin (bolus) plus lurbinectedin (1-h intravenous [i.v.] infusion) on Day 1 every three weeks (q3wk) as second-line therapy in relapsed small cell lung canc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::504713d6638c193ee1e101c7e76e1baf
https://pubmed.ncbi.nlm.nih.gov/33704620
https://pubmed.ncbi.nlm.nih.gov/33704620
Autor:
Eva Banus, Leyre Agreda, Lourdes Llanero, Antonio Nieto, Rubin Lubomirov, Gema Corral, Martin Cullell-Young, Rastilav Bahleda, Christophe Massard, Maria Vieito, Ali Zeaiter, Elena Y Cristoveanu, Cristian Fernandez, Salvador Fudio, Honey Kumar Oberoi, Santiago Ponce Aix, Luis Paz-Ares, Carmen Kahatt, Elena Garralda
Publikováno v:
Journal of Clinical Oncology. 39:3078-3078
3078 Background: PM14 is a new chemical entity that forms DNA adducts which specifically inhibit RNA synthesis and block active transcription of protein-coding genes. Antitumor activity has been demonstrated in vitro in several cell lines (e.g. lung,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ec94f6bfee72894b90b661217442938b
https://doi.org/10.1200/jco.2021.39.15_suppl.3078
https://doi.org/10.1200/jco.2021.39.15_suppl.3078
Autor:
Martin Cullell-Young, Noa Efrat, Joanne L. Blum, Pierfranco Conte, Suzette Delaloge, Anthony Gonçalves, Donald A. Richards, Marc Debled, Pilar Lardelli, Paul Richards, Antonio Nieto
Publikováno v:
Breast Cancer Research and Treatment. 155:295-302
Trabectedin is an alkylating agent that binds to the minor groove of DNA. Early studies with trabectedin suggested efficacy in triple-negative and HER2-overexpressing metastatic breast cancer (MBC). The efficacy and safety of trabectedin in pretreate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37252e3167de56a1964edac89f06986f
https://doi.org/10.1007/s10549-015-3675-x
https://doi.org/10.1007/s10549-015-3675-x
Autor:
Elizabeth Jimenez Aguilar, Santiago Ponce Aix, Gregory M. Cote, Eva Maria Gonzalez, Juan Manuel Sepúlveda, Luis Paz-Ares, Mariano Siguero, Ali Zeaiter, Monica Insa, Inmaculada Sanchez-Simon, Maria Jose Flor, Rafael Nuñez, Martin Cullell-Young, Alejandro Gonzalez, Carmen Kahatt
Publikováno v:
Journal of Clinical Oncology. 38:3514-3514
3514 Background: LUR is a novel agent that exerts antitumor activity through inhibition of trans-activated transcription and modulation of tumor microenvironment. Preclinical synergism/additivity in combination with IRI has been reported, thus prompt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::331f732465d7c48d89db0057ae5d1ade
https://doi.org/10.1200/jco.2020.38.15_suppl.3514
https://doi.org/10.1200/jco.2020.38.15_suppl.3514
Autor:
Ignace Vergote, Antonio Nieto, Cristian Fernandez, Carmen Kahatt, Martin Cullell-Young, Stephanie Gaillard, Alexandra Leary, Vivek Subbiah, Ali Zeaiter, Jose Manuel Trigo
Publikováno v:
Journal of Clinical Oncology. 38:3635-3635
3635 Background: Lurbinectedin (L), an inhibitor of active transcription, has shown activity in second-line (2L) small cell lung cancer (SCLC) (ASCO 2019). Topotecan (T) is the only approved drug in 2L SCLC and is also used in platinum resistant ovar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::df15680bc47b998a5f5fc75940ca735c
https://doi.org/10.1200/jco.2020.38.15_suppl.3635
https://doi.org/10.1200/jco.2020.38.15_suppl.3635
Autor:
Michael Flynn, Carmen Kahatt, Martin Forster, A. Soto Matos-Pita, J.A. Lopez-Vilariño, Carlos Fernández-Teruel, Victor Moreno, Mariano Siguero, Martin Cullell-Young, Emiliano Calvo, M.E. Olmedo, Esther Holgado, M.P. Lopez Criado
Publikováno v:
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Annals of Oncology
Consejería de Sanidad de la Comunidad de Madrid
Annals of Oncology
Background Lurbinectedin (PM01183) has synergistic antitumor activity when combined with doxorubicin in mice with xenografted tumors. This phase I trial determined the recommended dose (RD) of doxorubicin (bolus) and PM01183 (1-h intravenous infusion
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::858dae5a703a11916820f3dbe5502204
https://hdl.handle.net/20.500.12530/30265
https://hdl.handle.net/20.500.12530/30265
